Is acotinib/acalatinib a domestic drug or an imported drug?

In the domestic market, patients are often concerned about whether a new drug is domestically developed or imported. This not only involves price and accessibility, but also involves trust in drug quality and research and development background. Acalabrutinib (Acalabrutinib) is an innovative drug originally developed by overseas pharmaceutical companies and first launched in the international market. Acalabrutinib currently on the market in China is still an imported drug. In other words, there is no fully independently developed imitation version on the market in China.

As a new generation of BTK inhibitorsAcotinib was first developed by an American biopharmaceutical company and has been approved in many countries and regions around the world. In terms of research and development concept, it has been optimized with higher selectivity for the BTK pathway, thus maintaining the efficacy of treating chronic lymphocytic leukemia (CLL) while reducing some common adverse reactions. It is precisely this that makes it show better tolerability advantages when compared with the first-generation product ibrutinib, and has gradually become an important choice for clinicians.

Although acotinib currently on the market in China is still an imported drug, with its approval and medical insurance coverage, market demand is bound to grow rapidly. It is foreseeable that domestic pharmaceutical companies will also accelerate the research and development of generic drugs in the future to reduce overall drug costs and further expand patient accessibility. However, generic drugs usually require a long period of time from R&D to clinical to marketing, so in the short term, patients still have to rely on imported original drugs for treatment.

In general, acotinib’s import status does not affect its clinical value in China. On the contrary, its introduction means that Chinese patients can enjoy this innovative treatment simultaneously around the world. With the promotion of policies and the improvement of the industrial chain, the domestic version of acotinib may gradually become available in the future, further promoting the popularization and application of BTK inhibitors.

Reference materials:https://www.calquence.com/